đź“Š Evidence-Based Reference
philips 31 series in the ear hearing aid
Philips Hearing Instruments
Summary: The Philips 31 Series In The Ear Hearing Aid is a hearing device designed to assist individuals with hearing impairment. It is FDA-cleared and supported by 12 studies, though none directly related to this device.
FDA Clearance Information
Pathway
510K
Number
K921463 ↗
Decision Date
May 22, 1992
Product Code
ESD
Device Class
Class 1
Evidence
419 studies
The Philips 31 Series In The Ear Hearing Aid was cleared by the FDA through the 510(k) pathway on May 22, 1992. It is manufactured by Philips Hearing Instruments and classified as a Class 1 device under product code ESD.
What It Is
The Philips 31 Series In The Ear Hearing Aid is a device designed to amplify sound for individuals with hearing loss. It fits within the ear and is intended to improve auditory perception in patients with mild to moderate hearing impairment.
Clinical Applications
This hearing aid is commonly used in audiology clinics and hearing centers to assist patients with hearing loss. It is suitable for everyday use, providing enhanced sound amplification in various environments.
Evidence Summary
The available literature includes 12 studies, though none are directly related to the Philips 31 Series Hearing Aid. The studies span various topics and were published between 2024 and 2025.
Reported Outcomes
Published studies report outcomes related to other medical devices and conditions, not directly applicable to the Philips 31 Series Hearing Aid. No specific efficacy findings are available for this device.
Safety Profile
Reported complications include general device-related issues such as discomfort or improper fit, though specific safety data for the Philips 31 Series Hearing Aid is not available in the provided evidence.
Evidence Limitations
The evidence does not directly address the Philips 31 Series Hearing Aid, highlighting a gap in device-specific research. Further studies are needed to evaluate its efficacy and safety comprehensively.
Linked Studies (20)
PubMed • 2025
Onyx Liquid Embolic Agent: Basic Knowledge for Its Use in Interventional Neuroradiology.
Journal of neuroendovascular therapy
RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2025
Performance evaluation of quantitative hemoglobin A2 and fetal hemoglobin testing using commercially lyophilized vs. in-house whole blood controls in Chinese clinical laboratories: a 12-year analysis of National External Quality Assessment Data.
Clinical chemistry and laboratory medicine
RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2025
Clinical progress note: Haemophilus influenzae type b.
Journal of hospital medicine
RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2025
Pilot study of social media promotion of home-based self-testing for syphilis.
Sexually transmitted diseases
RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2025
Clinical development and performance of the First to Know Syphilis Self-Test for over-the-counter usage: a de novo rapid test for treponemal antibody.
Journal of clinical microbiology
View Source →
PubMed • 2025
Implementation of an Opt-Out and Rapid Point-of-Care Syphilis Testing Program for Pregnant Patients Presenting to the Emergency Department.
Sexually transmitted diseases
RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2025
Evaluation of Rapid Syphilis Testing Using the Syphilis Health Check in Florida, 2015-2016.
Florida public health review
View Source →
PubMed • 2025
Multiplex droplet digital PCR for the detection and quantitation of Streptococcus pneumoniae, Mycoplasma pneumoniae, and Haemophilus influenzae.
Frontiers in cellular and infection microbiology
RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2025
Palm Multidiagnostic of Mycoplasma pneumoniae, Chlamydia pneumoniae, Haemophilus influenzae, and Streptococcus pneumoniae Using One-Tube CRISPR/Cas12a.
Transboundary and emerging diseases
View Source →
PubMed • 2025
Tp40: a new potential prognostic and diagnostic marker for syphilis.
Microbiology spectrum
View Source →
PubMed • 2025
Serotonin sets up neutrophil extracellular traps to promote neuroendocrine prostate cancer metastasis in the liver.
The Journal of clinical investigation
RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2025
Application value of Philips Ingenuity TF PET/CT scanner imaging agent FAP in evaluating renal fibrosis.
Hellenic journal of nuclear medicine
RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2025
Message from Dr. Philippe T. Georgel, Guest Editor for the Marshall University Collection, Brad D. Smith, President of Marshall University, and Dr. Anivandan Mukherjee, Provost of Marshall University.
Biochemistry and cell biology = Biochimie et biologie cellulaire
View Source →
PubMed • 2025
Improved patient comfort and procedural efficiency using chlorhexidine-coated hydrophilic urethral catheters: a randomized controlled trial.
Journal of Yeungnam medical science
RCT View Source →
PubMed • 2025
pTx-Pulseq in hybrid sequences: Accessible and advanced hybrid open-source MRI sequences on Philips scanners.
Magnetic resonance in medicine
RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2025
Comparative connectomics of Drosophila descending and ascending neurons.
Nature
RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2025
Hydrophilic-coated sheaths for reducing radial artery spasm during transradial procedures: A systematic review and meta-analysis.
Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences
View Source →
PubMed • 2025
History of antineutrophil cytoplasmic autoantibodies : Milestones in rheumatology.
Zeitschrift fur Rheumatologie
View Source →
PubMed • 2025
A Hydrophilic Polyurethane Foam Containing Nigella sativa Oil as a Wound Dressing.
BioMed research international
RCT|prospective|retrospective|case Series|other View Source →Frequently Asked Questions
What are the clinical indications for Philips 31 Series In The Ear Hearing Aid?
The device is indicated for individuals with mild to moderate hearing loss requiring sound amplification.
What outcomes have been reported in clinical studies?
No specific outcomes have been reported for the Philips 31 Series Hearing Aid in the provided evidence.
What complications have been reported?
Safety data specific to the Philips 31 Series Hearing Aid is not available; general issues may include discomfort or improper fit.
Disclaimer: This page compiles publicly available regulatory and published clinical evidence for educational reference.
It does not constitute medical advice, product endorsement, or a recommendation for clinical use.
Always consult manufacturer documentation and clinical judgment for patient care decisions.